Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33results about How to "Enhances intestinal epithelial barrier function" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Pharmaceutical composition of nanoparticles
InactiveUS8257740B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPharmaceutical non-active ingredientsNanoparticleMedicine
The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial ermeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8535640B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleSurface charges
The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8361439B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8048404B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7998458B2Reduce resistanceEasy to transportIn-vivo radioactive preparationsPeptide/protein ingredientsMedicineNanoparticle
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS20120003306A1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryBiocideActive agentNanoparticle
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8202839B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8337811B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS7993625B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsNanoparticleMedicine
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a pegylated bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8354094B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7910086B1Reduce inflammatory responseEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsDrug deliveryActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7919072B1Reduce inflammationEnhances intestinal epithelial barrier functionIn-vivo radioactive preparationsPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses the bioactive nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8202508B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityIn-vivo radioactive preparationsPeptide/protein ingredientsActive agentSurface charges
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles for protein drug delivery
InactiveUS8048453B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS20110142927A1Reduce resistanceEasy to transportPeptide/protein ingredientsPharmaceutical non-active ingredientsMedicineActive agent
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8119102B1Sufficient solubilityEnhances intestinal epithelial barrier functionOrganic active ingredientsIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8287905B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityPowder deliveryPeptide/protein ingredientsEpithelial permeabilityMedicine
The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7988949B2Reduce resistanceEasy to transportNervous disorderIn-vivo radioactive preparationsNanoparticleMedicine
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7863259B1Reduce resistanceEasy to transportBiocidePeptide/protein ingredientsMedicineNanoparticle
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7901666B1Reduce resistanceEasy to transportIn-vivo radioactive preparationsPharmaceutical non-active ingredientsNanoparticleDrug biological activity
The invention discloses a pharmaceutical composition for treating a subject comprising two or more bioactive nanoparticles, thus treating the subject by co-administering the bioactive nanoparticles to the subject, wherein a first and a second bioactive nanoparticles comprise a shell portion that is dominated by positively charged chitosan, a core portion that contains negatively charged substrate, and at least a first bioactive agent in the first nanoparticle and a second bioactive agent in the second nanoparticle.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS8188042B1Reduce inflammationEnhances intestinal epithelial barrier functionOrganic active ingredientsPowder deliveryNanoparticleMedicine
The invention discloses bioactive nanoparticles composed of chitosan, poly-glutamic acid, and diethylenetriaminepentaacetic acid for use in radionuclide decorporation during radiological emergency. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8349799B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS20110142926A1Reduce resistanceEasy to transportPowder deliveryNervous disorderProtein insertionMedicine
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
InactiveUS7867984B1Reduce inflammationEnhances intestinal epithelial barrier functionBiocidePowder deliveryNanoparticleAppetite suppressing
The invention discloses the bioactive nanoparticles composed of chitosan, poly-glutamic acid, and at least one appetite-suppressing agent characterized with a positive surface charge and a method of treating obesity in a subject in need via their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8038985B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryOrganic active ingredientsNanoparticleActive agent
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of peptide drug and enzyme-inhibition compounds
InactiveUS20120121701A1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityAntibacterial agentsOrganic active ingredientsPeptide drugEnzyme inhibition
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS7998459B1Sufficient solubilityEnhances intestinal epithelial barrier functionPowder deliveryIn-vivo radioactive preparationsActive agentNanoparticle
The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Nanoparticles for protein drug delivery
The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8236281B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityIn-vivo radioactive preparationsAmine active ingredientsDiabetes mellitusNanoparticle
The invention relates to a pharmaceutical composition of nanoparticles, wherein the nanoparticles comprise positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating diabetes of an animal subject.
Owner:NANOMEGA MEDICAL CORP
Pharmaceutical composition of nanoparticles
InactiveUS8236752B1Enhances intestinal epithelial barrier functionReduce intestinal permeabilityBiocideAntimycoticsDiseaseNanoparticle
Owner:NANOMEGA MEDICAL CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com